US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
US5336762A
(en)
*
|
1985-11-18 |
1994-08-09 |
Access Pharmaceuticals, Inc. |
Polychelating agents for image and spectral enhancement (and spectral shift)
|
EP0247156B1
(fr)
*
|
1985-11-18 |
1993-06-23 |
Access Pharmaceuticals Inc. |
Agents polychelateurs pour l'amelioration de l'image et du spectre (et pour derive spectrale)
|
USRE38008E1
(en)
|
1986-10-09 |
2003-02-25 |
Neorx Corporation |
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
US5019368A
(en)
*
|
1989-02-23 |
1991-05-28 |
Cancer Biologics, Inc. |
Detection of necrotic malignant tissue and associated therapy
|
EP0273452B1
(fr)
*
|
1986-12-30 |
1994-03-23 |
Nihon Medi-Physics Co., Ltd. |
Composé de haut poids moléculaire comprenant une unité d'un composé dirigeant vers l'accepteur asialoglycoprotéinique et une unité d'un composé formant un chélate liée chimiquement à celui-ci et son utilisation
|
US5084266A
(en)
*
|
1988-02-03 |
1992-01-28 |
The University Of Melbourne |
Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
|
US5681543A
(en)
*
|
1988-02-29 |
1997-10-28 |
Shering Aktiengesellschaft |
Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
|
US4925648A
(en)
*
|
1988-07-29 |
1990-05-15 |
Immunomedics, Inc. |
Detection and treatment of infectious and inflammatory lesions
|
US5439665A
(en)
*
|
1988-07-29 |
1995-08-08 |
Immunomedics |
Detection and treatment of infectious and inflammatory lesions
|
US5213788A
(en)
*
|
1988-09-29 |
1993-05-25 |
Ranney David F |
Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
|
US5260050A
(en)
*
|
1988-09-29 |
1993-11-09 |
Ranney David F |
Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
|
GB2223572B
(en)
*
|
1988-10-04 |
1992-10-28 |
Rolls Royce Plc |
Detecting trapped material within a hollow article using radiation
|
ATE107502T1
(de)
*
|
1988-10-05 |
1994-07-15 |
Vestar Inc |
Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
|
US5948634A
(en)
*
|
1988-12-21 |
1999-09-07 |
The General Hospital Coporation |
Neural thread protein gene expression and detection of alzheimer's disease
|
US5059415A
(en)
*
|
1989-02-21 |
1991-10-22 |
The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health |
Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
|
US5308604A
(en)
*
|
1989-04-19 |
1994-05-03 |
Deutsches Krebsforschungsinstitut |
Conjugates for tumor localization and/or tumor therapy
|
US5230883A
(en)
*
|
1989-05-04 |
1993-07-27 |
Wisconsin Alumni Research Foundation |
Method for localization and treatment of tumors using polylysine complexes
|
US5114703A
(en)
*
|
1989-05-30 |
1992-05-19 |
Alliance Pharmaceutical Corp. |
Percutaneous lymphography using particulate fluorocarbon emulsions
|
JP2593963B2
(ja)
*
|
1989-11-27 |
1997-03-26 |
コンキャット リミティド |
常磁性カチオン及びポリホスホネートリガンドの錯体を用いての骨及び関連組織のmri像増強
|
KR0162259B1
(ko)
*
|
1989-12-05 |
1998-12-01 |
아미 펙터 |
감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
|
US5130129A
(en)
*
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
US5277892A
(en)
*
|
1990-08-08 |
1994-01-11 |
Rhomed Incorporated |
In vivo lymphocyte tagging
|
US5310539A
(en)
*
|
1991-04-15 |
1994-05-10 |
Board Of Regents, The University Of Texas System |
Melanin-based agents for image enhancement
|
WO1993000934A1
(fr)
*
|
1991-07-01 |
1993-01-21 |
Mallinckrodt Medical, Inc. |
Agents d'imagerie specifiques aux tissus comprenant des anticorps anti-idiotypiques permettant de produire des images internes
|
AU2687992A
(en)
*
|
1991-09-25 |
1993-04-27 |
Centocor Inc. |
Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof
|
US5643549A
(en)
*
|
1992-02-20 |
1997-07-01 |
Rhomed Incorporated |
Leukostimulatory agent for in vivo leukocyte tagging
|
AU4778893A
(en)
*
|
1992-07-21 |
1994-02-14 |
General Hospital Corporation, The |
System of drug delivery to the lymphatic tissues
|
US7713528B1
(en)
*
|
1993-02-18 |
2010-05-11 |
Enzo Therapeutics, Inc. |
Method for in vivo delivery of active compounds using reagent conjugate
|
US5595721A
(en)
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
DE69534233T2
(de)
|
1994-09-16 |
2005-10-27 |
Ethicon Endo-Surgery, Inc., Cincinnati |
Vorrichtungen zum bestimmen und markieren von gewebe
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US5994409A
(en)
*
|
1997-12-09 |
1999-11-30 |
U.S. Bioscience, Inc. |
Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
|
US7833528B2
(en)
*
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
US6361774B1
(en)
|
1999-09-17 |
2002-03-26 |
Immunomedics, Inc. |
Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
|
JP3793693B2
(ja)
|
1998-12-23 |
2006-07-05 |
ファイザー インコーポレーテッド |
Ctla−4に対するヒトモノクローナル抗体
|
US6682736B1
(en)
*
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
US7109003B2
(en)
*
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US6356782B1
(en)
*
|
1998-12-24 |
2002-03-12 |
Vivant Medical, Inc. |
Subcutaneous cavity marking device and method
|
US6371904B1
(en)
*
|
1998-12-24 |
2002-04-16 |
Vivant Medical, Inc. |
Subcutaneous cavity marking device and method
|
US9669113B1
(en)
|
1998-12-24 |
2017-06-06 |
Devicor Medical Products, Inc. |
Device and method for safe location and marking of a biopsy cavity
|
MY133346A
(en)
|
1999-03-01 |
2007-11-30 |
Biogen Inc |
Kit for radiolabeling ligands with yttrium-90
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
US6489312B1
(en)
*
|
1999-06-15 |
2002-12-03 |
Medimmune Oncology, Inc. |
Pharmaceutical formulations comprising aminoalkyl phosphorothioates
|
KR100996759B1
(ko)
|
1999-08-24 |
2010-11-25 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
US6835370B2
(en)
*
|
1999-11-08 |
2004-12-28 |
Rhode Island Hospital |
Diagnosis and treatment of malignant neoplasms
|
US20030031670A1
(en)
*
|
1999-11-08 |
2003-02-13 |
Jack R. Wands |
Diagnosis and treatment of malignant neoplasms
|
US20050123545A1
(en)
*
|
1999-11-08 |
2005-06-09 |
Wands Jack R. |
Diagnosis and treatment of malignant neoplasms
|
WO2002077172A2
(fr)
*
|
2001-03-23 |
2002-10-03 |
Board Of Regents, The University Of Texas System |
Methodes servant a inhiber l'angiogenese, la croissance tumorale et la metastase faisant appel a un anti-il8 et a un anti-muc18 entierement humains dans divers types de tumeurs
|
US7045605B2
(en)
|
2001-06-01 |
2006-05-16 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
WO2002100334A2
(fr)
*
|
2001-06-11 |
2002-12-19 |
University Of Miami |
Complexes radiopharmaceutiques permettant de tolerer une transplantation
|
WO2003024388A2
(fr)
|
2001-09-20 |
2003-03-27 |
Cornell Research Foundation, Inc. |
Methodes et compositions de traitement ou de prevention de troubles cutanes au moyen d'agents de liaison specifiques pour un antigene membranaire specifique de la prostate
|
US8323903B2
(en)
*
|
2001-10-12 |
2012-12-04 |
Life Technologies Corporation |
Antibody complexes and methods for immunolabeling
|
AR039067A1
(es)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
JP2005516965A
(ja)
*
|
2001-12-28 |
2005-06-09 |
アブジェニックス・インコーポレーテッド |
抗muc18抗体を使用する方法
|
ATE364618T1
(de)
*
|
2001-12-28 |
2007-07-15 |
Amgen Fremont Inc |
Antikörper gegen das muc18-antigen
|
ES2307824T3
(es)
*
|
2001-12-28 |
2008-12-01 |
Amgen Fremont Inc. |
Uso de anticuerpos contra el antigeno muc18.
|
US6578724B1
(en)
*
|
2001-12-29 |
2003-06-17 |
United States Can Company |
Connector for use in packaging aerosol containers
|
AU2003225793A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Baxter Healthcare S.A. |
Methods and compositions for directing cells to target organs
|
SI1503794T1
(sl)
*
|
2002-04-12 |
2012-09-28 |
Medarex Inc |
Postopek zdravljenja z uporabo ctla-4 antiteles
|
MXPA05003843A
(es)
*
|
2002-10-10 |
2006-02-17 |
Us Dept Veterans Affairs |
Deteccion, localizacion y determicnacion de fases de tumores usando linfocitos activados rotulados dirigidos a un epitope especifico.
|
AU2003286493A1
(en)
*
|
2002-10-18 |
2004-05-04 |
Abgenix, Inc. |
System and method for cleaving antibodies
|
US7285269B2
(en)
|
2002-12-02 |
2007-10-23 |
Amgen Fremont, Inc. |
Antibodies directed to tumor necrosis factor
|
WO2004052194A1
(fr)
*
|
2002-12-12 |
2004-06-24 |
Manoa Medical, Inc. |
Ablation percutanee d'un ganglion lymphatique sentinelle identifie par imagerie de contraste
|
EP1581794B1
(fr)
|
2003-01-10 |
2008-09-17 |
Millennium Pharmaceuticals, Inc. |
Procede pour determiner la reapparition du cancer de la prostate
|
CA2519528C
(fr)
|
2003-03-19 |
2016-01-26 |
Abgenix, Inc. |
Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
|
WO2005021494A2
(fr)
*
|
2003-06-13 |
2005-03-10 |
Immunomedics, Inc. |
Peptides d'acides amines d
|
CA2530172A1
(fr)
*
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Anticorps contre les mutants de deletion du recepteur du facteur de croissance epidermique et utilisations
|
EP1660519B1
(fr)
*
|
2003-07-29 |
2014-05-14 |
Immunomedics, Inc. |
Conjugués comprenant le 2-[18F]-fluoro-2-désoxy-D-glucose et une molécule peptidique
|
EP1802341A1
(fr)
|
2004-07-16 |
2007-07-04 |
Pfizer Products Inc. |
Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
|
DK1827492T3
(da)
|
2004-11-30 |
2010-11-22 |
Curagen Corp |
Antistoffer rettet mod GPNMB og anvendelser deraf
|
US7572444B2
(en)
|
2004-12-20 |
2009-08-11 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
US7612180B2
(en)
|
2005-03-03 |
2009-11-03 |
Immunomedics, Inc. |
Humanized L243 antibodies
|
EP3153525A1
(fr)
|
2005-03-23 |
2017-04-12 |
Genmab A/S |
Anticorps dirigés contre cd38 pour le traitement du myélome multiple
|
EP3058955B1
(fr)
|
2005-03-24 |
2019-05-29 |
Millennium Pharmaceuticals, Inc. |
Anticorps se liant à l'ov064 et leurs procédés d'utilisation
|
CA2615460A1
(fr)
*
|
2005-08-08 |
2007-02-15 |
Onconon, Llc |
Compositions d'anticorps, methodes de traitement de maladie neoplasique et methodes de regulation de la fertilite
|
CN101287507B
(zh)
*
|
2005-08-12 |
2012-12-05 |
刘江 |
用于淋巴靶向的方法和装置
|
EP1957115B8
(fr)
|
2005-11-10 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
|
EP1954311A4
(fr)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
Régimes d'escalade de dose d'anticorps ctla-4
|
RS52357B
(en)
|
2005-12-13 |
2012-12-31 |
Medimmune Limited |
BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
|
EP2674440B1
(fr)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Ensembles bioactifs à base d'immunoglobuline multivalent
|
BRPI0709481A2
(pt)
*
|
2006-04-07 |
2011-07-19 |
Government Of The Us Secretary Dept Of Health And Human Services |
anticorpo monoclonal isolado, anticorpo monoclonal humano isolado, composição farmacêutica, anticorpo anti-igf-i e anti-igf-ii recombinante isolado ou fragmento de ligação ao antìgeno do mesmo, método para detectar o fator i e o fator ii de crescimento insulina humana em uma amostra, método para dectetar o fator i de crescimento insulina humana em uma amostra, ácido nucléico isolado, célula recombinante , célula hospedeira ,método para preparar um anticorpo, método para preparar um anticorpo, método para tratar uma doença neoplásica em um indivìduo mamìfero, método para diagnosticar doença neoplásica em um indivìduo mamìfero e método para classificar um composto candidato a fármaco
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
WO2010072740A2
(fr)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Agents de liaison ciblés dirigés contre α5β1 et leurs applications
|
CN102458437B
(zh)
|
2009-05-05 |
2015-06-10 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
AR078751A1
(es)
|
2009-10-23 |
2011-11-30 |
Millennium Pharm Inc |
Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
LT2580243T
(lt)
|
2010-06-09 |
2020-01-27 |
Genmab A/S |
Antikūnai prieš žmogaus cd38
|
ES2647388T3
(es)
|
2010-06-15 |
2017-12-21 |
Genmab A/S |
Conjugados farmacológicos de anticuerpos humanos contra factor tisular
|
US20120201821A1
(en)
|
2010-10-25 |
2012-08-09 |
Gonzalez Jr Lino |
Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
|
WO2012099871A1
(fr)
|
2011-01-17 |
2012-07-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulation de l'activité de lrch4 et ses applications thérapeutiques
|
WO2012136552A1
(fr)
|
2011-04-08 |
2012-10-11 |
H. Lundbeck A/S |
Anticorps spécifiquement dirigés contre la protéine bêta-amyloïde pyroglutamatée
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
EP2780040A1
(fr)
|
2011-11-16 |
2014-09-24 |
Amgen Inc. |
Procédé de traitement de troubles associés au mutant de délétion viii du récepteur du facteur de croissance épidermique
|
MY169341A
(en)
|
2012-02-06 |
2019-03-21 |
Inhibrx Inc |
Cd47 antibodies and methods of use thereof
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
EP2869845B1
(fr)
|
2012-07-06 |
2019-08-28 |
Genmab B.V. |
Protéine dimérique ayant des mutations triples
|
EP3632462A1
(fr)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Protéine dimérique ayant des mutations triples
|
KR20220156667A
(ko)
|
2013-01-10 |
2022-11-25 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
KR102276974B1
(ko)
|
2013-02-06 |
2021-07-13 |
인히브릭스, 인크. |
비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
|
US9931412B2
(en)
|
2013-02-08 |
2018-04-03 |
The Regents Of The University Of Michigan |
Targeted theranostics
|
EP2970415B1
(fr)
|
2013-03-14 |
2018-12-19 |
Regeneron Pharmaceuticals, Inc. |
Protéines de fusion d'apéline et leurs utilisations
|
EP3033356B1
(fr)
|
2013-08-14 |
2020-01-15 |
Sachdev Sidhu |
Anticorps contre les protéines frizzled et leurs méthodes d'utilisation
|
US20150050697A1
(en)
|
2013-08-19 |
2015-02-19 |
Abbott Molecular Inc. |
Nucleotide analogs
|
WO2015103026A2
(fr)
|
2014-01-03 |
2015-07-09 |
The Regents Of The University Of Michigan |
Traitement des troubles neurologiques
|
JP2017518737A
(ja)
|
2014-04-21 |
2017-07-13 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
SYK標的治療薬のための抗pSYK抗体分子及びその使用
|
EP3166688B1
(fr)
|
2014-07-08 |
2024-08-21 |
New York University |
Ligands de visualisation de tau et leurs utilisations dans le diagnostic et le traitement de tauopathies
|
SG11201610777VA
(en)
|
2014-07-11 |
2017-01-27 |
Genmab As |
Antibodies binding axl
|
WO2016086036A2
(fr)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Méthodes et compositions pour radiomarquage au 18f de produits biologiques
|
CA2981312C
(fr)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Regions constantes de chaines lourdes presentant une liaison reduite aux recepteurs fc gamma
|
EP3730520A1
(fr)
|
2015-07-10 |
2020-10-28 |
Genmab A/S |
Conjugués anticorps-médicament spécifiques d'axl pour le traitement du cancer
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
CN108137679B
(zh)
|
2015-08-13 |
2022-07-19 |
纽约大学 |
对Tau的{p}Ser404表位有选择性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
|
CN108135986B
(zh)
|
2015-08-13 |
2022-07-29 |
纽约大学 |
对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
|
LT3458111T
(lt)
|
2016-05-19 |
2021-05-25 |
Bristol-Myers Squibb Company |
Pet vizualizacijos imunomoduliatoriai
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
MY197836A
(en)
|
2016-07-12 |
2023-07-20 |
H Lundbeck As |
Antibodies specific for hyperphosphorylated tau and methods of use thereof
|
SG11201903693QA
(en)
|
2016-11-01 |
2019-05-30 |
Genmab Bv |
Polypeptide variants and uses thereof
|
MA47019A
(fr)
|
2016-12-16 |
2021-04-21 |
H Lundbeck As |
Agents, utilisations et procédés
|
MA47205A
(fr)
|
2017-01-04 |
2019-11-13 |
H Lundbeck As |
Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
US10882915B2
(en)
|
2017-10-24 |
2021-01-05 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of CD117+ cells
|
US20210107988A1
(en)
|
2018-01-24 |
2021-04-15 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
SG11202012993SA
(en)
|
2018-07-13 |
2021-02-25 |
Genmab As |
Variants of cd38 antibody and uses thereof
|
KR20220003572A
(ko)
|
2019-04-24 |
2022-01-10 |
하이델베르크 파마 리서치 게엠베하 |
아마톡신 항체-약물 결합체 및 이의 용도
|
MX2022008391A
(es)
|
2020-01-10 |
2022-09-29 |
Kling Biotherapeutics B V |
Anticuerpos epiteliales específicos de cadherina.
|
EP3909601A1
(fr)
|
2020-05-11 |
2021-11-17 |
LeukoCom GmbH |
Nouvel anticorps se liant spécifiquement au ceacam 1/3/5 humain et son utilisation
|